For many people living with obesity, newer weight-loss medicines such as Wegovy and Mounjaro have been transformative. These drugs are often grouped under the label GLP-1 medicines because they mimic hormones released after eating, helping people feel fuller and less hungry. Mounjaro, whose active ingredient is tirzepatide, also acts on another hormone involved in appetite and blood sugar control.
At a time when more than 1 billion people worldwide are living with obesity, these medicines are widely viewed as among the biggest advances in obesity treatment. But one important question is becoming harder to avoid: what happens when people stop taking them?
